{"id":111500,"date":"2024-04-18T08:59:00","date_gmt":"2024-04-18T01:59:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/20240418085900111500"},"modified":"2024-04-19T00:24:56","modified_gmt":"2024-04-18T16:24:56","slug":"%e9%99%86%e9%81%93%e5%9f%b9%e5%8c%bb%e5%ad%a6%e5%9b%a2%e9%98%9f%e6%90%ba18%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e9%97%aa%e8%80%80%e7%ac%ac50%e5%b1%8a%e6%ac%a7%e6%b4%b2%e8%a1%80%e6%b6%b2","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/20240418085900111500","title":{"rendered":"\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u643a18\u9879\u7814\u7a76\u6210\u679c\u95ea\u8000\u7b2c50\u5c4a\u6b27\u6d32\u8840\u6db2\u4e0e\u9aa8\u9ad3\u79fb\u690d\u5b66\u4f1a\u5e74\u4f1a"},"content":{"rendered":"

\u5317\u4eac<\/span>2024\u5e744\u670818\u65e5<\/span> \/\u7f8e\u901a\u793e\/ — 2024\u5e74\u7b2c50\u5c4a\u6b27\u6d32\u8840\u6db2\u4e0e\u9aa8\u9ad3\u79fb\u690d\u5b66\u4f1a(EBMT)\u5e74\u4f1a\u4e8e2024\u5e744\u670814-17\u65e5\u5728\u82f1\u56fd\u683c\u62c9\u65af\u54e5\u4e3e\u884c\uff0c\u4f5c\u4e3a\u4e45\u8d1f\u76db\u540d\u7684\u56fd\u9645\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\u9886\u57df\u76db\u4f1a\uff0c\u672c\u6b21EBMT\u5e74\u4f1a\u89c4\u6a21\u5b8f\u5927\uff0c\u6c47\u805a\u5168\u7403\u8fd18000\u4f59\u540d\u8840\u6db2\u75c5\u9886\u57df\u4e13\u5bb6\u5b66\u8005\uff0c\u8bbe\u7f6e76\u4e2a\u5206\u4f1a\u573a\uff0c\u56f4\u7ed5\u8fd1\u5e74\u6765\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\u548c\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u524d\u6cbf<\/span>\u70ed\u70b9\u95ee\u9898\u8fdb\u884c\u6df1\u5ea6\u63a2\u8ba8\u3002<\/p>\n

\n

\"\u9646\u9053\u57f9\u533b\u7597\u56e2\u961fEBMT\u4f1a\u8bae\u73b0\u573a\u5408\u5f71\"<\/a>
\u9646\u9053\u57f9\u533b\u7597\u56e2\u961fEBMT\u4f1a\u8bae\u73b0\u573a\u5408\u5f71<\/span><\/p>\n<\/p><\/div>\n

\u672c\u5c4a\u4f1a\u8bae\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u4ee3\u8868\u643a18\u9879\u7814\u7a76\u6210\u679c\u8d74\u82f1\u73b0\u573a\u53c2\u4f1a\uff0c\u5176\u4e2d1\u9879\u53e3\u5934\u62a5\u544a\uff0c\u5185\u5bb9\u6db5\u76d6\u4e86\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\u548c\u7ec6\u80de\u514d\u75ab\u6cbb\u7597\u9886\u57df\u6700\u524d\u6cbf\u7684\u8fdb\u5c55\u53ca\u4e34\u5e8a\u68c0\u9a8c\u7684\u76f8\u5173\u7814\u7a76\uff0c\u62a5\u544a\u4ece\u6570\u91cf\u548c\u8d28\u91cf\u4e0a\u90fd\u4f4d\u4e8e\u524d\u5217\uff0c\u5c55\u793a\u51fa\u56e2\u961f\u5353\u8d8a\u7684\u533b\u7597\u6280\u672f\u6c34\u5e73\u4ee5\u53ca\u84ec\u52c3\u7684\u521b\u65b0\u80fd\u529b\uff0c\u4e5f\u662f\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u5168\u7403\u5f71\u54cd\u529b\u7684\u6700\u4f73\u5370\u8bc1\u3002<\/p>\n

\n

\"\u9646\u9053\u57f9\u533b\u9662\u9aa8\u9ad3\u79fb\u690d\u79d1\u80e5\u65b9\u533b\u751f\u4ee3\u8868\u5362\u5cb3\u6559\u6388\u56e2\u961f\u5728EBMT\u4e0a\u505a\u53e3\u5934\u53d1\u8a00\"<\/a>
\u9646\u9053\u57f9\u533b\u9662\u9aa8\u9ad3\u79fb\u690d\u79d1\u80e5\u65b9\u533b\u751f\u4ee3\u8868\u5362\u5cb3\u6559\u6388\u56e2\u961f\u5728EBMT\u4e0a\u505a\u53e3\u5934\u53d1\u8a00<\/span><\/p>\n<\/p><\/div>\n

\u5f53\u5730\u65f6\u95f4\uff0c4\u670816\u65e5\u4e0b\u534815\uff1a15\uff0c\u7531\u9646\u9053\u57f9\u533b\u9662\u9aa8\u9ad3\u79fb\u690d\u79d1\u80e5\u65b9\u533b\u751f\u4ee3\u8868\u5362\u5cb3\u4e3b\u4efb\u56e2\u961f\u5728"Optimising donor Choice"\u73af\u8282\u4e2d\uff0c\u53e3\u5934\u6c47\u62a5\u4e86"Comparing the Outcomes of Using Non-First-Degree Related Donors to First-Degree Related Donors in Haploidentical HSCT for Hematological Malignancies: A Case-Control Analysis"\u7684\u4e34\u5e8a\u7814\u7a76\u6210\u679c\uff0c\u7814\u7a76\u8bc1\u5b9e\u4e86\u5728\u5355\u500d\u4f53\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\u4e2d\uff0c\u91c7\u7528\u975e\u76f4\u7cfb\u4f9b\u4f53\u5728\u7597\u6548\u53ca\u5b89\u5168\u6027\u65b9\u9762\u5747\u53ef\u4ee5\u4e0e\u76f4\u7cfb\u4f9b\u4f53\u76f8\u5ab2\u7f8e\uff0c\u8fd9\u4e5f\u4e3a\u4e34\u5e8a\u4e0a\u6269\u5c55\u5355\u500d\u4f53\u79fb\u690d\u4f9b\u8005\u7684\u53ef\u9009\u62e9\u8303\u56f4\u63d0\u4f9b\u4e86\u8fdb\u4e00\u6b65\u7684\u8bc1\u636e\u652f\u6301\u3002\u5362\u5cb3\u4e3b\u4efb\u56e2\u961f\u8fd9\u4e00\u9879\u7814\u7a76\u53d7\u5230\u4e86\u9887\u591a\u5173\u6ce8\u3002<\/p>\n

\u80e5\u65b9\u533b\u751f\u7684\u53e3\u5934\u62a5\u544a\u903b\u8f91\u6e05\u6670\u3001\u6761\u7406\u5206\u660e\uff0c\u65e2\u5c55\u73b0\u4e86\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u7684\u4e13\u4e1a\u7d20\u517b\uff0c\u53c8\u4f53\u73b0\u4e86\u56e2\u961f\u9752\u5e74\u533b\u5e08\u5bf9\u5b66\u672f\u7814\u7a76\u7684\u70ed\u60c5\u4e0e\u8ffd\u6c42\u3002\u73b0\u573a\u4e13\u5bb6\u5bf9\u5362\u5cb3\u4e3b\u4efb\u56e2\u961f\u7684\u6b64\u9879\u7814\u7a76\u6210\u679c\u8868\u73b0\u51fa\u6781\u5927\u7684<\/span>\u5174\u8da3\uff0c\u8868\u793a\u6b64\u9879\u7814\u7a76\u4e3a\u6ca1\u6709\u76f4\u7cfb\u4f9b\u8005\u7684\u60a3\u8005\u5e26\u6765\u4e86\u798f\u97f3\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u672c\u73af\u8282\u7684\u53e3\u5934\u62a5\u544a\u8d28\u91cf\u4e0a\u4e58\uff0c\u4f17\u591a\u62a5\u544a\u5185\u5bb9\u6db5\u76d6EBMT\u5b98\u65b9\u76f8\u5173\u7684\u591a\u4e2d\u5fc3\u6df1\u5165\u7814\u7a76\uff0c\u80fd\u591f\u8363\u5e78\u5165\u9009\u8fd9\u4e00\u73af\u8282\u53e3\u5934\u62a5\u544a\uff0c\u8db3\u4ee5\u8bc1\u660e\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u5728\u79fb\u690d\u9886\u57df\u7684\u5353\u8d8a\u8868\u73b0\uff0c\u51f8\u663e\u4e86\u6211\u4eec\u56e2\u961f\u5728\u5b66\u672f\u7814\u7a76\u4e0a\u7684\u5e7f\u9614\u89c6\u91ce\u4e0e\u6df1\u8fdc\u5f71\u54cd\u529b\u3002<\/p>\n

\u9664\u53e3\u5934\u62a5\u544a\u5916\uff0c\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u768417\u9879\u5899\u62a5\u5c55\u793a\u9646\u7eed\u4eae\u76f8\uff0c\u5176\u4e2d12\u7bc7\u62a5\u544a\u7531\u56e2\u961f\u9752\u5e74\u533b\u5e08\u4f5c\u4e3a\u7b2c\u4e00\u4f5c\u8005\u3002\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u4e00\u8d2f\u91cd\u89c6\u9752\u5e74\u9aa8\u5e72\u533b\u751f\u7684\u57f9\u517b\uff0c\u533b\u9662\u4e0e\u79d1\u5ba4\u56e2\u961f\u4e0d\u65ad\u4f18\u5316\u4eba\u624d\u57f9\u517b\u73af\u5883\uff0c\u52aa\u529b\u4e3a\u9752\u5e74\u533b\u751f\u7684\u6210\u957f\u521b\u9020\u6761\u4ef6\u3001\u642d\u5efa\u5e73\u53f0\uff0c\u9f13\u52b1\u4ed6\u4eec"\u8d70\u51fa\u53bb"\uff0c\u901a\u8fc7\u53c2\u52a0\u56fd\u5185\u56fd\u9645\u8fdb\u4fee\u57f9\u8bad\uff0c\u53c2\u4e0e\u56fd\u9645\u5b66\u672f\u4f1a\u8bae\uff0c\u4e0d\u65ad\u6df1\u5316\u5bf9\u533b\u5b66\u9886\u57df\u7684\u7406\u89e3\uff0c\u63d0\u5347\u5b66\u672f\u7d20\u517b\uff0c\u6253\u9020\u4e00\u652f\u7d20\u8d28\u4f18\u826f\u3001\u582a\u5f53\u91cd\u4efb\u7684\u9752\u5e74\u533b\u5e08\u961f\u4f0d\u3002<\/p>\n

\u6df1\u601d\u783a\u89c1\uff0c\u5171\u7b51\u672a\u6765\u3002\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u575a\u6301\u8d70\u51fa\u53bb\uff0c\u7d27\u8ddf\u56fd\u9645\u524d\u6cbf\uff0c\u805a\u7126\u5f53\u4e0b\u8840\u6db2\u75c5\u9886\u57df\u91cd\u96be\u6311\u6218\uff0c\u4e0d\u65ad\u8fdb\u884c\u5b66\u672f\u521b\u65b0\uff0c\u6269\u5c55\u4e34\u5e8a\u5b9e\u8df5\uff0c\u4f18\u5316\u8bca\u7597\u7b56\u7565\uff0c\u7a81\u7834\u4f20\u7edf\u6cbb\u7597"\u5929\u82b1\u677f"\uff0c\u529b\u6c42\u6700\u5927\u7a0b\u5ea6\u6539\u5584\u6cbb\u7597\u6548\u679c\uff0c\u4e3a\u5e7f\u5927\u8840\u6db2\u75c5\u60a3\u8005\u5e26\u6765\u66f4\u591a\u5e0c\u671b\u548c\u6e29\u6696\u3002<\/p>\n

EBMT 2024 \u6210\u679c\u4e00\u89c8<\/b><\/p>\n

\u53e3\u5934\u62a5\u544a (ORAL)<\/span><\/b><\/p>\n

\u6458\u8981\u53f7\uff1a959
\u7b2c\u4e00\u4f5c\u8005\uff1a\u5362\u5cb3\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u5362\u5cb3
\u9898\u76ee\uff1aComparing the Outcomes of Using Non-First-Degree Related Donors to First-Degree Related Donors in Haploidentical HSCT for Hematological Malignancies: A Case-Control Analysis<\/p>\n

\u5899\u62a5\u5c55\u793a\uff08<\/b>POSTER\uff09<\/b><\/p>\n

\u6458\u8981\u53f7\uff1a257
\u7b2c\u4e00\u4f5c\u8005\uff1a\u6731\u4f1a\u4e3d\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u9b4f\u5fd7\u6770 
\u9898\u76ee\uff1aEfficacy and Safety Analysis of Prophylactic Basiliximab Vedotin Administration after Pediatric Acute Leukemia Haploidentical Hematopoietic Stem Cell Transplantation<\/p>\n

\u6458\u8981\u53f7\uff1a284
\u7b2c\u4e00\u4f5c\u8005\uff1a\u4f55\u6d77\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u5b59\u745e\u5a1f 
\u9898\u76ee\uff1aIntensive Conditioning Regimen for Allogeneic Hematopoietic Stem Cell can Overcome the Poor Prognosis of T(6;9)\/DEK-NUP214 AML<\/p>\n

\u6458\u8981\u53f7\uff1a391
\u7b2c\u4e00\u4f5c\u8005\uff1a\u989c\u8ff0\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u5218\u5fb7\u7430
\u9898\u76ee\uff1aThe Clinical Analysis of Allogeneic Hematopoietic Stem Cell Transplantation in Therapy-Related Myeloid Neoplasms<\/p>\n

\u6458\u8981\u53f7\uff1a733
\u7b2c\u4e00\u4f5c\u8005\uff1a\u6f58\u98de\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u9b4f\u5fd7\u6770
\u9898\u76ee\uff1aClinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation Using Busulfan\/Cyclophosphamide and Melphalan or Thiotepa as Conditioning Regimen in 37 Patients with Acute Megakaryoblastic Leukemia<\/p>\n

\u6458\u8981\u53f7\uff1a835
\u7b2c\u4e00\u4f5c\u8005\uff1a\u8d75\u8273\u4e3d\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u8d75\u8273\u4e3d
\u9898\u76ee\uff1aAllogeneic Transplantation Using Myeloablative Conditioning Regimes is Safe and Effective in Elderly Patients Over 60 Years with AML and MDS<\/p>\n

\u6458\u8981\u53f7\uff1a967
\u7b2c\u4e00\u4f5c\u8005\uff1a\u540c\u683c\u4e50   \u901a\u8baf\u4f5c\u8005\uff1a\u5362\u5cb3
\u9898\u76ee\uff1aTLS\u2237ERG<\/span> Fusion Gene Predicts A Poor Prognosis after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Single Center Study<\/p>\n

\u6458\u8981\u53f7\uff1a998
\u7b2c\u4e00\u4f5c\u8005\uff1a\u9b4f\u5fd7\u6770\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u9b4f\u5fd7\u6770
\u9898\u76ee\uff1aHaploidentical Hematopoietic Cell Transplantation with Unrelated Cord Blood Enhances Survival and Reduces the Incidence of aGVHD for Pediatric Acute Myeloid Leukemia<\/p>\n

\u6458\u8981\u53f7\uff1a1070
\u7b2c\u4e00\u4f5c\u8005\uff1a\u8463\u78ca\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u66f9\u661f\u7389
\u9898\u76ee\uff1aAnalysis of the Efficacy of Luspatercept in the Treatment of Anemia after Allogeneic Haematopoietic Stem Cell Transplantation<\/p>\n

\u6458\u8981\u53f7\uff1a1074
\u7b2c\u4e00\u4f5c\u8005\uff1a\u9a6c\u8587\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u66f9\u661f\u7389
\u9898\u76ee\uff1aRituximab for the Treatment of Steroid-Refractory Oral Chronic Graft-Versus-Host Disease after Allo-Hematopoietic Stem Cell Transplantation<\/p>\n

\u6458\u8981\u53f7\uff1a1102
\u7b2c\u4e00\u4f5c\u8005\uff1a\u6f58\u98de\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u9b4f\u5fd7\u6770
\u9898\u76ee\uff1aEfficacy Analysis of Haploidentical Transplantation Using Busulfan\/Cyclophosphamide and Melphalan as Conditioning Regimen for Relapsed and Refractory Acute Myeloid Leukemia<\/p>\n

\u6458\u8981\u53f7\uff1a1103
\u7b2c\u4e00\u4f5c\u8005\uff1a\u80e5\u65b9\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u5362\u5cb3
\u9898\u76ee\uff1aDiagnosis of Mucormycosis in Allogeneic Hematopoietic Stem Cell Transplantation Using Metagenomic Next-Generation Sequencing: A Single-Center Clinical Study<\/p>\n

\u6458\u8981\u53f7\uff1a1306
\u7b2c\u4e00\u4f5c\u8005\uff1a\u674e\u6960\u6960\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u5f20\u5efa\u5e73
\u9898\u76ee\uff1aAllogeneic Hematopoietic Stem Cell Transplantation with Bu(2)\/Cy\/Flu\/ATG can Achieve Good Results in Treatment of Transfusion Dependent Non-Severe Aplastic Anemia<\/p>\n

\u6458\u8981\u53f7\uff1a1338
\u7b2c\u4e00\u4f5c\u8005\uff1a\u5b59\u745e\u5a1f\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u5b59\u745e\u5a1f
\u9898\u76ee\uff1aComparisons of Safety and Efficacy of Allo-HSCT after CAR T-Cell or Chemotherapy-Based Complete Remission in Pediatric T-ALL<\/p>\n

\u6458\u8981\u53f7\uff1a1730
\u7b2c\u4e00\u4f5c\u8005\uff1a\u738b\u4e1c\u51fa\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u738b\u5349
\u9898\u76ee\uff1aRelevant Studies on Cytokines Level and CAR-T Expansion Associated to CD7 CAR-T Therapy<\/p>\n

\u6458\u8981\u53f7\uff1a1743
\u7b2c\u4e00\u4f5c\u8005\uff1a\u5f20\u5efa\u5e73\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u5f20\u5efa\u5e73
\u9898\u76ee\uff1aATLG has Better Safety than RATG in the Treatment of Adult AA with Allogeneic Hematopoietic Stem Cell Transplantation<\/p>\n

\u6458\u8981\u53f7\uff1a1748
\u7b2c\u4e00\u4f5c\u8005\uff1a\u9648\u66fc\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u738b\u5349
\u9898\u76ee\uff1aStratification and Immunologic Analysis of Patients with SARS-CoV-2 Infection after Hematopoietic Stem Cell Transplantation<\/p>\n

\u6458\u8981\u53f7\uff1a1755
\u7b2c\u4e00\u4f5c\u8005\uff1a\u5f20\u5efa\u5e73\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u5f20\u5efa\u5e73
\u9898\u76ee\uff1aStudy on The Efficacy and Safety of Blinatumomab Maintenance Therapy of High Risk Ph Negative ALL after Allo-HSCT<\/p>\n

\n\n\n\n
\n

\u6ce8\uff1a\u4e0a\u8ff0\u7814\u7a76\u6210\u679c\u6309\u6458\u8981\u53f7\u6392\u5e8f<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

 <\/p>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

\u5317\u4eac2024\u5e744\u670818\u65e5 \/\u7f8e\u901a\u793e\/ — 2024\u5e74\u7b2c50\u5c4a\u6b27\u6d32\u8840\u6db2\u4e0e\u9aa8\u9ad3\u79fb\u690d\u5b66\u4f1a(EBMT)\u5e74\u4f1a\u4e8e2024\u5e744\u670814-17\u65e5\u5728\u82f1\u56fd\u683c\u62c9\u65af\u54e5\u4e3e\u884c\uff0c\u4f5c\u4e3a\u4e45\u8d1f\u76db\u540d\u7684\u56fd\u9645\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\u9886\u57df\u76db\u4f1a\uff0c\u672c\u6b21EBMT\u5e74\u4f1a\u89c4\u6a21\u5b8f\u5927\uff0c\u6c47\u805a\u5168\u7403\u8fd18000\u4f59\u540d\u8840\u6db2\u75c5\u9886\u57df\u4e13\u5bb6\u5b66\u8005\uff0c\u8bbe\u7f6e76\u4e2a\u5206\u4f1a\u573a\uff0c\u56f4\u7ed5\u8fd1\u5e74\u6765\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\u548c\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u524d\u6cbf\u70ed\u70b9\u95ee\u9898\u8fdb\u884c\u6df1\u5ea6\u63a2\u8ba8\u3002 \u9646\u9053\u57f9\u533b\u7597\u56e2\u961fEBMT\u4f1a\u8bae\u73b0\u573a\u5408\u5f71 \u672c\u5c4a\u4f1a\u8bae\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u4ee3\u8868\u643a18\u9879\u7814\u7a76\u6210\u679c\u8d74\u82f1\u73b0\u573a\u53c2\u4f1a\uff0c\u5176\u4e2d1\u9879\u53e3\u5934\u62a5\u544a\uff0c\u5185\u5bb9\u6db5\u76d6\u4e86\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\u548c\u7ec6\u80de\u514d\u75ab\u6cbb\u7597\u9886\u57df\u6700\u524d\u6cbf\u7684\u8fdb\u5c55\u53ca\u4e34\u5e8a\u68c0\u9a8c\u7684\u76f8\u5173\u7814\u7a76\uff0c\u62a5\u544a\u4ece\u6570\u91cf\u548c\u8d28\u91cf\u4e0a\u90fd\u4f4d\u4e8e\u524d\u5217\uff0c\u5c55\u793a\u51fa\u56e2\u961f\u5353\u8d8a\u7684\u533b\u7597\u6280\u672f\u6c34\u5e73\u4ee5\u53ca\u84ec\u52c3\u7684\u521b\u65b0\u80fd\u529b\uff0c\u4e5f\u662f\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u5168\u7403\u5f71\u54cd\u529b\u7684\u6700\u4f73\u5370\u8bc1\u3002 \u9646\u9053\u57f9\u533b\u9662\u9aa8\u9ad3\u79fb\u690d\u79d1\u80e5\u65b9\u533b\u751f\u4ee3\u8868\u5362\u5cb3\u6559\u6388\u56e2\u961f\u5728EBMT\u4e0a\u505a\u53e3\u5934\u53d1\u8a00 \u5f53\u5730\u65f6\u95f4\uff0c4\u670816\u65e5\u4e0b\u534815\uff1a15\uff0c\u7531\u9646\u9053\u57f9\u533b\u9662\u9aa8\u9ad3\u79fb\u690d\u79d1\u80e5\u65b9\u533b\u751f\u4ee3\u8868\u5362\u5cb3\u4e3b\u4efb\u56e2\u961f\u5728"Optimising donor Choice"\u73af\u8282\u4e2d\uff0c\u53e3\u5934\u6c47\u62a5\u4e86"Comparing the Outcomes of Using Non-First-Degree Related Donors to First-Degree Related Donors in Haploidentical HSCT for Hematological Malignancies: A Case-Control Analysis"\u7684\u4e34\u5e8a\u7814\u7a76\u6210\u679c\uff0c\u7814\u7a76\u8bc1\u5b9e\u4e86\u5728\u5355\u500d\u4f53\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\u4e2d\uff0c\u91c7\u7528\u975e\u76f4\u7cfb\u4f9b\u4f53\u5728\u7597\u6548\u53ca\u5b89\u5168\u6027\u65b9\u9762\u5747\u53ef\u4ee5\u4e0e\u76f4\u7cfb\u4f9b\u4f53\u76f8\u5ab2\u7f8e\uff0c\u8fd9\u4e5f\u4e3a\u4e34\u5e8a\u4e0a\u6269\u5c55\u5355\u500d\u4f53\u79fb\u690d\u4f9b\u8005\u7684\u53ef\u9009\u62e9\u8303\u56f4\u63d0\u4f9b\u4e86\u8fdb\u4e00\u6b65\u7684\u8bc1\u636e\u652f\u6301\u3002\u5362\u5cb3\u4e3b\u4efb\u56e2\u961f\u8fd9\u4e00\u9879\u7814\u7a76\u53d7\u5230\u4e86\u9887\u591a\u5173\u6ce8\u3002 \u80e5\u65b9\u533b\u751f\u7684\u53e3\u5934\u62a5\u544a\u903b\u8f91\u6e05\u6670\u3001\u6761\u7406\u5206\u660e\uff0c\u65e2\u5c55\u73b0\u4e86\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u7684\u4e13\u4e1a\u7d20\u517b\uff0c\u53c8\u4f53\u73b0\u4e86\u56e2\u961f\u9752\u5e74\u533b\u5e08\u5bf9\u5b66\u672f\u7814\u7a76\u7684\u70ed\u60c5\u4e0e\u8ffd\u6c42\u3002\u73b0\u573a\u4e13\u5bb6\u5bf9\u5362\u5cb3\u4e3b\u4efb\u56e2\u961f\u7684\u6b64\u9879\u7814\u7a76\u6210\u679c\u8868\u73b0\u51fa\u6781\u5927\u7684\u5174\u8da3\uff0c\u8868\u793a\u6b64\u9879\u7814\u7a76\u4e3a\u6ca1\u6709\u76f4\u7cfb\u4f9b\u8005\u7684\u60a3\u8005\u5e26\u6765\u4e86\u798f\u97f3\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u672c\u73af\u8282\u7684\u53e3\u5934\u62a5\u544a\u8d28\u91cf\u4e0a\u4e58\uff0c\u4f17\u591a\u62a5\u544a\u5185\u5bb9\u6db5\u76d6EBMT\u5b98\u65b9\u76f8\u5173\u7684\u591a\u4e2d\u5fc3\u6df1\u5165\u7814\u7a76\uff0c\u80fd\u591f\u8363\u5e78\u5165\u9009\u8fd9\u4e00\u73af\u8282\u53e3\u5934\u62a5\u544a\uff0c\u8db3\u4ee5\u8bc1\u660e\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u5728\u79fb\u690d\u9886\u57df\u7684\u5353\u8d8a\u8868\u73b0\uff0c\u51f8\u663e\u4e86\u6211\u4eec\u56e2\u961f\u5728\u5b66\u672f\u7814\u7a76\u4e0a\u7684\u5e7f\u9614\u89c6\u91ce\u4e0e\u6df1\u8fdc\u5f71\u54cd\u529b\u3002 \u9664\u53e3\u5934\u62a5\u544a\u5916\uff0c\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u768417\u9879\u5899\u62a5\u5c55\u793a\u9646\u7eed\u4eae\u76f8\uff0c\u5176\u4e2d12\u7bc7\u62a5\u544a\u7531\u56e2\u961f\u9752\u5e74\u533b\u5e08\u4f5c\u4e3a\u7b2c\u4e00\u4f5c\u8005\u3002\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u4e00\u8d2f\u91cd\u89c6\u9752\u5e74\u9aa8\u5e72\u533b\u751f\u7684\u57f9\u517b\uff0c\u533b\u9662\u4e0e\u79d1\u5ba4\u56e2\u961f\u4e0d\u65ad\u4f18\u5316\u4eba\u624d\u57f9\u517b\u73af\u5883\uff0c\u52aa\u529b\u4e3a\u9752\u5e74\u533b\u751f\u7684\u6210\u957f\u521b\u9020\u6761\u4ef6\u3001\u642d\u5efa\u5e73\u53f0\uff0c\u9f13\u52b1\u4ed6\u4eec"\u8d70\u51fa\u53bb"\uff0c\u901a\u8fc7\u53c2\u52a0\u56fd\u5185\u56fd\u9645\u8fdb\u4fee\u57f9\u8bad\uff0c\u53c2\u4e0e\u56fd\u9645\u5b66\u672f\u4f1a\u8bae\uff0c\u4e0d\u65ad\u6df1\u5316\u5bf9\u533b\u5b66\u9886\u57df\u7684\u7406\u89e3\uff0c\u63d0\u5347\u5b66\u672f\u7d20\u517b\uff0c\u6253\u9020\u4e00\u652f\u7d20\u8d28\u4f18\u826f\u3001\u582a\u5f53\u91cd\u4efb\u7684\u9752\u5e74\u533b\u5e08\u961f\u4f0d\u3002 \u6df1\u601d\u783a\u89c1\uff0c\u5171\u7b51\u672a\u6765\u3002\u9646\u9053\u57f9\u533b\u5b66\u56e2\u961f\u575a\u6301\u8d70\u51fa\u53bb\uff0c\u7d27\u8ddf\u56fd\u9645\u524d\u6cbf\uff0c\u805a\u7126\u5f53\u4e0b\u8840\u6db2\u75c5\u9886\u57df\u91cd\u96be\u6311\u6218\uff0c\u4e0d\u65ad\u8fdb\u884c\u5b66\u672f\u521b\u65b0\uff0c\u6269\u5c55\u4e34\u5e8a\u5b9e\u8df5\uff0c\u4f18\u5316\u8bca\u7597\u7b56\u7565\uff0c\u7a81\u7834\u4f20\u7edf\u6cbb\u7597"\u5929\u82b1\u677f"\uff0c\u529b\u6c42\u6700\u5927\u7a0b\u5ea6\u6539\u5584\u6cbb\u7597\u6548\u679c\uff0c\u4e3a\u5e7f\u5927\u8840\u6db2\u75c5\u60a3\u8005\u5e26\u6765\u66f4\u591a\u5e0c\u671b\u548c\u6e29\u6696\u3002 EBMT 2024 \u6210\u679c\u4e00\u89c8 \u53e3\u5934\u62a5\u544a (ORAL) \u6458\u8981\u53f7\uff1a959\u7b2c\u4e00\u4f5c\u8005\uff1a\u5362\u5cb3\uff0c\u901a\u8baf\u4f5c\u8005\uff1a\u5362\u5cb3\u9898\u76ee\uff1aComparing the Outcomes of Using Non-First-Degree Related Donors to First-Degree Related Donors in Haploidentical HSCT for Hematological… Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":111504,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-111500","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/111500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=111500"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/111500\/revisions"}],"predecessor-version":[{"id":111503,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/111500\/revisions\/111503"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/111504"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=111500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=111500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=111500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}